Real-world schedule de-escalation of teclistamab in patients with relapsed/refractory multiple myeloma

被引：0
|
作者：
Tan, Carlyn Rose Co
Derkach, Andriy
Maclachlan, Kylee
Hultcrantz, Malin
Hassoun, Hani
Mailankody, Sham
Shah, Urvi A.
Rajeeve, Sridevi
Shah, Gunjan L.
Scordo, Michael
Chung, David J.
Landau, Heather Jolie
Giralt, Sergio
Lesokhin, Alexander M.
Korde, Neha
Lin, Dee
Wu, Bingcao
Fowler, Jessica
Fernandez, Mariana
Usmani, Saad Zafar
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, New York, NY USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY USA
[4] Johnson & Johnson Innovat Med, Horsham, PA USA
[5] Johnson & Johnson Innovat Med, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7536
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Safety and Efficacy of Teclistamab in Patients with Relapsed/ Refractory Multiple Myeloma: A Real-World Experience
    Dima, Danai
    Davis, James A.
    Ahmed, Nausheen
    Jia, Xuefei
    Sannareddy, Aishwarya
    Shaikh, Hira
    Shune, Leyla
    Kaur, Gurbakhash
    Khouri, Jack
    Afrough, Aimaz
    Strouse, Christopher
    Lochner, Jonathan
    Mahmoudjafari, Zahra
    Raza, Shahzad
    Valent, Jason
    Anderson Jr, Larry D.
    Anwer, Faiz
    Abdallah, Al-Ola
    Hashmi, Hamza
    [J]. TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (03):
  • [2] Real-World Evaluation of Teclistamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
    Asoori, Sireesha
    Popat, Rakesh
    Martinez-Lopez, Joaquin
    Kastritis, Efstathios
    Brunaldi, Larissa
    Bansal, Radhika
    Corraes, Andre De Menezes Silva
    Yong, Kwee
    Mactier, Catriona
    Corona, Magdalena
    Saez Marin, Adolfo Jesus
    Fotiou, Despina
    Dimopoulos, Meletios Athanasios
    Chhabra, Saurabh
    Ailawadhi, Sikander
    Parrondo, Ricardo
    Martin, Thomas
    Durie, Brian G. M.
    Lin, Yi
    [J]. BLOOD, 2023, 142
  • [3] Teclistamab for Relapsed/Refractory Multiple Myeloma: Real-World Experience in an Early Access Program
    Uttervall, Katarina
    Nahi, Hareth
    Kashif, Muhammad
    Lemonakis, Konstantinos
    Rosengren, Sara
    Brolin, Janaki
    Lund, Johan
    Hansson, Markus
    [J]. BLOOD, 2022, 140 : 12605 - 12606
  • [4] Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
    Meera Mohan
    Jorge Monge
    Nishi Shah
    Danny Luan
    Mark Forsberg
    Vineel Bhatlapenumarthi
    Metodi Balev
    Anannya Patwari
    Heloise Cheruvalath
    Divaya Bhutani
    Sharmilan Thanendrarajan
    Binod Dhakal
    Maurizio Zangari
    Samer Al-Hadidi
    Dennis Cooper
    Suzanne Lentzsch
    Frits van Rhee
    Anita D’Souza
    Aniko Szabo
    Carolina Schinke
    Rajshekhar Chakraborty
    [J]. Blood Cancer Journal, 14
  • [5] Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study
    Mohan, Meera
    Shah, Nishi
    Luan, Danny
    Monge, Jorge
    Forsberg, Mark
    Bhatlapenumarthi, Vineel
    Balev, Metodi
    Patwari, Anannya
    Cheruvalath, Heloise
    Bhutani, Divaya
    Thanendrarajan, Sharmilan
    Dhakal, Binod
    Zangari, Maurizio
    Al Hadidi, Samer
    Cooper, Dennis L.
    Lentzsch, Suzanne
    van Rhee, Frits
    D'Souza, Anita
    Szabo, Aniko
    Schinke, Carolina
    Chakraborty, Rajshekhar
    [J]. BLOOD, 2023, 142
  • [6] Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
    Mohan, Meera
    Monge, Jorge
    Shah, Nishi
    Luan, Danny
    Forsberg, Mark
    Bhatlapenumarthi, Vineel
    Balev, Metodi
    Patwari, Anannya
    Cheruvalath, Heloise
    Bhutani, Divaya
    Thanendrarajan, Sharmilan
    Dhakal, Binod
    Zangari, Maurizio
    Al-Hadidi, Samer
    Cooper, Dennis
    Lentzsch, Suzanne
    van Rhee, Frits
    D'Souza, Anita
    Szabo, Aniko
    Schinke, Carolina
    Chakraborty, Rajshekhar
    [J]. BLOOD CANCER JOURNAL, 2024, 14 (01)
  • [7] Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma
    Dima, Danai
    Davis, James A.
    Ahmed, Nausheen
    Sannareddy, Aishwarya
    Shaikh, Hira
    Mahmoudjafari, Zahra
    Khouri, Jack
    Kaur, Gurbakhash
    Strouse, Christopher
    Valent, Jason
    Larry, Anderson D., Jr.
    Anwer, Faiz
    Abdallah, Al-Ola
    Hashmi, Hamza
    [J]. BLOOD, 2023, 142
  • [8] Teclistamab in Relapsed/Refractory Multiple Myeloma: Real-World Outcomes at a Single Academic Center in the Midwest
    Stepanovic, Adam
    Abonour, Rafat
    Abu Zaid, Mohammad
    Farag, Sherif
    Lee, Kelvin P.
    Suvannasankha, Attaya
    [J]. BLOOD, 2023, 142
  • [9] Real World Evaluation of Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM)
    Maringanti, Sireesha Asoori
    Lin, Yi
    Estritis, Stathis
    Martinez-Lopez, Joaquin
    Bansal, Radhika
    Fotiou, Despina
    Corona, Magdalena
    Chhabra, Saurabh
    Brunaldi, Larissa
    Corraes, Andre De Menezes Silva
    Parrondo, Ricardo
    Kapoor, Prashant
    Ailawadhi, Sikander
    Mas, Reyes
    Tamayo, Andrea
    Dimopoulos, Meletios
    Durie, Brian
    Martin, Thomas
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S506 - S507
  • [10] Real World Evaluation of Teclistamab: A Focus on Infections in Patients With Relapsed Refractory Multiple Myeloma (RRMM)
    Asoori, Sireesha
    Martin, Thomas
    Wolf, Jeffrey
    Chung, Alfred
    Arora, Shagun
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S536 - S537
12345